{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:40:24Z","timestamp":1791913224383,"version":"4.3.4"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Introduction:<\/jats:bold>\n                    Oil palm phenolic (OPP) is an antioxidant aqueous palm oil by-product and contains a high amount of phenolics. OPP has been proven to have many therapeutical benefits, and one of them is as an antihyperlipidemic agent. The previous phase 1 clinical trial proved OPP was safe to be orally consumed by healthy volunteers and yielded a good lipid profile. Thus, this phase 2 clinical trial was conducted to determine the effectiveness of OPP in improving the lipid profile among hyperlipidemic subjects.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    A parallel, placebo-controlled, randomized, double-blinded clinical trial was conducted for 2\u00a0months on 50 hyperlipidemic subjects aged 20\u201350\u00a0years old. The subjects were randomly distributed to two treatment arms with 25 participants each: control\/placebo (11 males and 14 females) and 250\u00a0mg of OPP (10 males and 15 females). The subjects were required to consume one capsule per day for 60\u00a0days. Fasting blood sampling for routine blood profile (hematology, liver function, renal function, and lipid) analysis and a medical examination were conducted at baseline, day 30, and day 60.\n                    <jats:italic>t<\/jats:italic>\n                    -test analysis was used to compare the difference between two test groups.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    The baseline lipid profile between control group (TC, 5.78 \u00b1 0.52\u00a0mmol\/L; LDL, 3.88 \u00b1 0.51\u00a0mmol\/L; HDL, 1.30 \u00b1 0.25; TG, 1.30 \u00b1 0.82), and 250\u00a0mg OPP (TC, 5.76 \u00b1 0.54\u00a0mmol\/L; LDL, 3.82 \u00b1 0.59\u00a0mmol\/L; HDL, 1.37 \u00b1 0.34; TG, 1.25 \u00b1 0.54) is insignificant. No serious adverse events (SAEs) were reported. No abnormality in fasting blood parameters in all groups was found. Compared to the control group among male participants, the 250\u00a0mg OPP group showed an improved serum triglyceride level. There were no statistically significant changes in all blood parameters from day 1 to day 60 with the exception of triglyceride level.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    The absence of SAEs reported and no abnormal findings in biochemistry and hematology results suggested that the 250\u00a0mg OPP was safe to be taken by hyperlipidemic patients with a high probability of reducing triglyceride level in hyperlipidemic male patients The outcomes from this phase II trial suggest that by incorporating OPP supplements into the diet may be a promising strategy for individuals with hyperlipidemia to improve their lipid profiles and reduce cardiovascular risk. However, more research is needed to fully understand the mechanisms of action and establish the long-term efficacy and safety of OPP supplementation in larger scale.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Limitation:<\/jats:bold>\n                    Small samples size hence lack of diversity (25 subjects per groups) and early sharing of treatment-response results.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Clinical Trial Registration:<\/jats:bold>\n                    <jats:ext-link>clinicaltrials.gov<\/jats:ext-link>\n                    , identifier NCT04573218.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2023.1190663","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T07:27:02Z","timestamp":1688714822000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety and efficacy of oil palm phenolic supplementation in improving lipid profile among hyperlipidemic adults: a phase 2, randomized, double-blind, placebo-controlled clinical trial"],"prefix":"10.3389","volume":"14","author":[{"given":"Nur Balqis","family":"Muhammad Ismail Tadj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurul `Izzah","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tg Mohd Ikhwan","family":"Tg Abu Bakar Sidik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S.","family":"Zulfarina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qodriyah","family":"Haji Mohd Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon-Sen","family":"Leow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Fairus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isa","family":"Naina Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"B1","volume-title":"Cellular and molecular immunology E-book","author":"Abbas","year":"2014"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2515690X18765945","DOI":"10.1177\/2515690X18765945","article-title":"Utilization of complementary and alternative medicine in multiethnic population: The Malaysian cohort study","volume":"23","author":"Abdullah","year":"2018","journal-title":"J. Evid. Based Integr. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12889-022-12595-1","article-title":"Prevalence and factors associated with lipid-lowering medications use for primary and secondary prevention of cardiovascular diseases among Malaysians: The REDISCOVER study","volume":"22","author":"Baharudin","year":"2022","journal-title":"BMC Public Health"},{"key":"B4","first-page":"319","article-title":"Antioxidant properties of palm fruit extracts","volume":"14","author":"Balasundram","year":"2005","journal-title":"Asia Pac J. Clin. Nutr."},{"key":"B5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.molonc.2015.02.011","article-title":"The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research","volume":"9","author":"Berry","year":"2015","journal-title":"Mol. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1007\/s11096-016-0350-1","article-title":"Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia","volume":"38","author":"Beshir","year":"2016","journal-title":"Int. J. Clin. Pharm."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1017\/jns.2014.3","article-title":"Anti-diabetic effects of palm fruit juice in the Nile rat (Arvicanthis niloticus)","volume":"3","author":"Bolsinger","year":"2014","journal-title":"J. Nutr. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.2337\/ds16-0084","article-title":"DASH eating plan: An eating pattern for diabetes management","volume":"30","author":"Campbell","year":"2017","journal-title":"Diabetes Spectr."},{"key":"B9","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1503\/cmaj.109-5053","article-title":"Is withholding clinical trial results\" research misconduct\"?","volume":"187","author":"Collier","year":"2015","journal-title":"Can. Med. Assoc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1016\/j.freeradbiomed.2006.02.017","article-title":"Mechanisms of H2O2-induced oxidative stress in endothelial cells","volume":"40","author":"Coyle","year":"2006","journal-title":"Free Radic. Biol. Med."},{"key":"B11","unstructured":"Statistics on causes of death, Malaysia, 20162017"},{"key":"B12","unstructured":"Statistics on causes of death, Malaysia, 20212022"},{"key":"B13","volume-title":"The effectiveness of red palm oil in patients with gastrointestinal diseases","author":"Ermatov","year":"2019"},{"key":"B14","volume-title":"Small clinical trials: Issues and challenges (vol. 1). Washington (DC): Institute of medicine (US) committee on strategies for small-number-participant clinical research trials","author":"Evans","year":"2001"},{"key":"B15","doi-asserted-by":"publisher","first-page":"8217","DOI":"10.1038\/s41598-018-26384-7","article-title":"A phase I single-blind clinical trial to evaluate the safety of oil palm phenolics (OPP) supplementation in healthy volunteers","volume":"8","author":"Fairus","year":"2018","journal-title":"Sci. Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1200\/JCO.2012.45.2086","article-title":"Recommendations for the return of research results to study participants and guardians: A report from the children's oncology group","volume":"30","author":"Fernandez","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1740774508089459","article-title":"Maintaining confidentiality of interim data to enhance trial integrity and credibility","volume":"5","author":"Fleming","year":"2008","journal-title":"Clin. Trials"},{"key":"B18","doi-asserted-by":"publisher","first-page":"471","DOI":"10.7326\/0003-4819-75-3-471","article-title":"An international classification of hyperlipidemias and hyperlipoproteinemias","volume":"75","author":"Fredrickson","year":"1971","journal-title":"Ann. Intern. Med."},{"key":"B19","first-page":"A6443","article-title":"Liver disorders in adults: ALT and AST","volume":"157","author":"Goorden","year":"2013","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"B20","first-page":"17","article-title":"A review on laboratory liver function tests","volume":"3","author":"Gowda","year":"2009","journal-title":"Pan Afr. Med. J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1200\/JCO.1987.5.9.1477","article-title":"Policies for study monitoring and interim reporting of results","volume":"5","author":"Green","year":"1987","journal-title":"J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0134030","DOI":"10.1371\/journal.pone.0134030","article-title":"Personal continuity of care in a university-based primary care practice: Impact on blood pressure control","volume":"10","author":"Hanafi","year":"2015","journal-title":"PloS one"},{"key":"B23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ctcp.2009.02.003","article-title":"Use of complementary and alternative medicine among patients with chronic diseases at outpatient clinics","volume":"15","author":"Hasan","year":"2009","journal-title":"Complement. Ther. Clin. Pract."},{"key":"B24","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jff.2014.01.002","article-title":"Oil palm phenolics and vitamin E reduce atherosclerosis in rabbits","volume":"7","author":"Idris","year":"2014","journal-title":"J. Funct. foods"},{"key":"B25","volume-title":"Integrated addendum to ICH E6 (R1): Guideline for good clinical practice, E6 (R2)","year":"2016"},{"key":"B26","volume-title":"NCDs - non-communicable diseases: Risk factors and other health problems","year":"2019"},{"key":"B27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-021-00284-z","article-title":"Acute kidney injury","volume":"7","author":"Kellum","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B28","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1093\/cvr\/cvn120","article-title":"Cytokines and atherosclerosis: A comprehensive review of studies in mice","volume":"79","author":"Kleemann","year":"2008","journal-title":"Cardiovasc. Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/9781119117810.ch5","article-title":"Risk factors for cardiovascular disease","author":"Kucia","year":"2022","journal-title":"Card. Care"},{"key":"B30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ctcp.2014.03.001","article-title":"Hypertensive patients' preferences for complementary and alternative medicine and the influence of these preferences on the adherence to prescribed medication","volume":"20","author":"Lee","year":"2014","journal-title":"Complementary Ther. Clin. Pract."},{"key":"B31","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/1471-2164-12-432","article-title":"Differential transcriptomic profiles effected by oil palm phenolics indicate novel health outcomes","volume":"12","author":"Leow","year":"2011","journal-title":"BMC Genomics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00394-012-0346-0","article-title":"Oil palm phenolics attenuate changes caused by an atherogenic diet in mice","volume":"52","author":"Leow","year":"2013","journal-title":"Eur. J. Nutr."},{"key":"B33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ctim.2004.11.002","article-title":"Complementary and alternative medicine use in multiracial Singapore","volume":"13","author":"Lim","year":"2005","journal-title":"Complement. Ther. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/nutrit\/nuw054","article-title":"Health-promoting effects of red palm oil: Evidence from animal and human studies","volume":"75","author":"Loganathan","year":"2017","journal-title":"Nutr. Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1039\/c5fo01083g","article-title":"Palm oil and cardiovascular disease: A randomized trial of the effects of hybrid palm oil supplementation on human plasma lipid patterns","volume":"7","author":"Lucci","year":"2016","journal-title":"Food Funct."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.29219\/fnr.v62.1353","article-title":"Effects of dietary palm olein on the cardiovascular risk factors in healthy young adults","volume":"62","author":"Lv","year":"2018","journal-title":"Food and Nutr. Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.yrtph.2017.05.021","article-title":"Safety evaluation of water-soluble palm fruit bioactives","volume":"88","author":"Lynch","year":"2017","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"B38","unstructured":"Obesity diagnosis2022"},{"key":"B39","volume-title":"Clinical practice guidelines: Management of dyslipidemia, 5th edition. Putrajaya, Malaysia","year":"2017"},{"key":"B40","volume-title":"Direct health-care cost of noncommunicable diseases in Malaysia","year":"2022"},{"key":"B41","volume-title":"The impact of noncommunicable diseases and their risk factors on Malaysia\u2019s gross domestic product","year":"2020"},{"key":"B42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12872-021-01956-0","article-title":"High prevalence of dyslipidaemia subtypes and their associated personal and clinical attributes in Malaysian adults: The REDISCOVER study","volume":"21","author":"Mohamed-Yassin","year":"2021","journal-title":"BMC Cardiovasc. Disord."},{"key":"B43","volume-title":"Effect of oil palm phenolics on beta amyloid deposition in cholesterol induced rat model of Alzheimer's disease: Histological evidence","author":"Monplaisir","year":"2016"},{"key":"B44","article-title":"A phase 1, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and tolerance of oil palm phenolics (OPP) in healthy volunteers","volume":"1686","author":"Muhammad Ismail Tadj","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B45","volume-title":"Role of red palm oil in male obesity and infertility prevention","author":"Olabiyi","year":"2021"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3390\/ijms17071176","article-title":"Protective effect of salicornia europaea extracts on high salt intake-induced vascular dysfunction and hypertension","volume":"17","author":"Panth","year":"","journal-title":"Int. J. Mol. Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"9152732","DOI":"10.1155\/2016\/9152732","article-title":"Reactive oxygen species: A key hallmark of cardiovascular disease","volume":"2016","author":"Panth","year":"","journal-title":"Adv. Med."},{"key":"B48","volume-title":"Dyslipidemia StatPearls. Treasure island (FL): StatPearls publishing copyright \u00a9 2022","author":"Pappan","year":"2022"},{"key":"B49","doi-asserted-by":"publisher","first-page":"S170","DOI":"10.2337\/dc08-s247","article-title":"NADPH oxidases, reactive oxygen species, and hypertension: Clinical implications and therapeutic possibilities","volume":"31","author":"Paravicini","year":"2008","journal-title":"Diabetes Care"},{"key":"B50","volume-title":"Hypertension\/hyperlipidemia\/hyperhomocysteinemia and nutrition approaches Handbook of Clinical Nutrition and Stroke (pp 81\u201394","author":"Patton","year":"2013"},{"key":"B51","doi-asserted-by":"publisher","first-page":"142898","DOI":"10.1155\/2013\/142898","article-title":"Role of complementary and alternative medicine in cardiovascular diseases","volume":"2013","author":"Qidwai","year":"2013","journal-title":"Evidence-based complementary Altern. Med. eCAM"},{"key":"B52","first-page":"119","article-title":"An ethnographic study of HDL-SEX (hypertension, diabetes, Hyperlipidemia-Smoking, overEating, eXercise) explanatory models of cardiovascular diseases","volume":"38","author":"Ramiro","year":"2000","journal-title":"Philipp. Herbs Suppl. Res. Database"},{"key":"B53","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-23458-8_1","volume-title":"Kidney anatomy and physiology","author":"Rayner","year":"2016"},{"key":"B54","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12913-015-0916-y","article-title":"Understanding the modifiable health systems barriers to hypertension management in Malaysia: A multi-method health systems appraisal approach","volume":"15","author":"Risso-Gill","year":"2015","journal-title":"BMC health Serv. Res."},{"key":"B55","article-title":"Polyphenol rich oil palm leaves extract reduce hyperglycaemia and lipid oxidation in STZ-rats","volume":"18","author":"Rosalina Tan","year":"2011","journal-title":"Int. Food Res. J."},{"key":"B56","doi-asserted-by":"publisher","first-page":"957105","DOI":"10.1155\/2015\/957105","article-title":"Age- and gender-related differences in LDL-cholesterol management in outpatients with type 2 diabetes mellitus","volume":"2015","author":"Russo","year":"2015","journal-title":"Int. J. Endocrinol."},{"key":"B57","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/2229-3485.71856","article-title":"Sample size estimation in clinical trial","volume":"1","author":"Sakpal","year":"2010","journal-title":"Perspect. Clin. Res."},{"key":"B58","volume-title":"Treatment of vegetation liquors derived from oil-bearing fruit: Google Patents","author":"Sambanthamurthi","year":"2008"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1017\/S0007114511002121","article-title":"Oil palm vegetation liquor: A new source of phenolic bioactives","volume":"106","author":"Sambanthamurthi","year":"2011","journal-title":"Br. J. Nutr."},{"key":"B60","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.tcb.2007.07.009","article-title":"ROS, mitochondria and the regulation of autophagy","volume":"17","author":"Scherz-Shouval","year":"2007","journal-title":"ROS, mitochondria Regul. autophagy"},{"key":"B61","first-page":"495","article-title":"Effects of oil palm phenolics on tumor cells in vitro and in vivo","volume":"4","author":"Sekaran","year":"2010","journal-title":"Afr. J. Food Sci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2147\/PPA.S69680","article-title":"A qualitative study on hypertensive care behavior in primary health care settings in Malaysia","volume":"8","author":"Shima","year":"2014","journal-title":"Patient Prefer. adherence"},{"key":"B63","volume-title":"Small n clinical trials in the regulatory setting. Presentation to the institute of medicine committee on strategies for small-number-participant clinical research trials, september 28","author":"Siegel","year":"2000"},{"key":"B64","doi-asserted-by":"publisher","first-page":"711","DOI":"10.7150\/ijms.29934","article-title":"The pharmacological potential of oil palm phenolics (OPP) individual components","volume":"16","author":"Syarifah-Noratiqah","year":"2019","journal-title":"Int. J. Med. Sci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.3390\/nu10091315","article-title":"Tocotrienol-rich vitamin E from palm oil (tocovid) and its effects in diabetes and diabetic nephropathy: A pilot phase II clinical trial","volume":"10","author":"Tan","year":"2018","journal-title":"Nutrients"},{"key":"B66","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41467-021-21116-4","article-title":"The effects of releasing early results from ongoing clinical trials","volume":"12","author":"Ventz","year":"2021","journal-title":"Nat. Commun."},{"key":"B67","first-page":"402","article-title":"The role of oxidative stress in atherosclerosis","volume":"50","author":"Vogiatzi","year":"2009","journal-title":"role oxidative stress Atheroscler."},{"key":"B68","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/s0163-7258(00)00114-5","article-title":"Oxidative pathways in cardiovascular disease: Roles, mechanisms, and therapeutic implications","volume":"89","author":"Wattanapitayakul","year":"2001","journal-title":"Pharmacol. Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12906-018-2160-6","article-title":"Why people use herbal medicine: Insights from a focus-group study in Germany","volume":"18","author":"Welz","year":"2018","journal-title":"BMC Complementary Altern. Med."},{"key":"B70","first-page":"342","volume-title":"Strategy for intention to treat analysis in randomised trials with missing outcome data","author":"White","year":"2011"},{"key":"B71","unstructured":"Cardiovascular diseases (CVDs)2021"},{"key":"B72","unstructured":"The annual health-care cost of cardiovascular diseases, diabetes and cancer in Malaysia exceeds RM 9.65 billion2022"},{"key":"B73","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/apha.12515","article-title":"Biological and physiological role of reactive oxygen species\u2013the good, the bad and the ugly","volume":"214","author":"Zuo","year":"2015","journal-title":"Acta physiol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1190663\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T16:16:12Z","timestamp":1729700172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1190663\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":73,"alternative-id":["10.3389\/fphar.2023.1190663"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1190663","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]},"article-number":"1190663"}}